Edgewise Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Edgewise Therapeutics is gedaald met een gemiddeld jaarlijks tempo van -41.1%, terwijl de winst van de sector Pharmaceuticals jaarlijks groeide met 1.2%.

Belangrijke informatie

-41.1%

Groei van de winst

86.1%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	n/a
Rendement op eigen vermogen	-25.4%
Nettomarge	n/a
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

Nov 26

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Sep 19

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Aug 12

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Aug 05

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

May 10

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

May 10

Edgewise Therapeutics: Behind The Massive Rally

Feb 18

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Dec 07

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Aug 16

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Apr 28

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Jan 13

Edgewise Therapeutics proposes $100M stock offering plan

Sep 13

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Aug 04

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Aug 02

Opbrengsten en kosten

Hoe Edgewise Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:EWTX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	-124	29	118
30 Jun 24	-116	26	110
31 Mar 24	-106	25	99
31 Dec 23	-100	23	91
30 Sep 23	-89	23	80
30 Jun 23	-81	21	70
31 Mar 23	-76	20	63
31 Dec 22	-68	18	54
30 Sep 22	-61	16	47
30 Jun 22	-56	15	42
31 Mar 22	-51	13	38
31 Dec 21	-43	11	32
30 Sep 21	-36	8	28
30 Jun 21	-27	6	22
31 Mar 21	-21	3	17
31 Dec 20	-17	2	15

Kwaliteitswinsten: EWTX is momenteel verliesgevend.

Groeiende winstmarge: EWTX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: EWTX is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 41.1% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van EWTX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: EWTX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 54.6% ).

Rendement op eigen vermogen

Hoge ROE: EWTX heeft een negatief Return on Equity ( -25.42% ), omdat het momenteel verliesgevend is.

Edgewise Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Edgewise Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Edgewise Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Edgewise Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Recent updates

Here's Why We're Not Too Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Situation

New major risk - Revenue and earnings growth

Edgewise Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

General Counsel exercised options and sold US$1.9m worth of stock

Chief Financial Officer recently sold US$830k worth of stock

Chief Financial Officer notifies of intention to sell stock

New major risk - Share price stability

Price target increased by 11% to US$36.67

Edgewise: Stock Is Bouncing On Heart Disease Drug Data, Albeit From Just 7 Patients (Rating Upgrade)

Edgewise Therapeutics, Inc Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Edgewise Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

New major risk - Revenue and earnings growth

Edgewise Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

High number of new directors

Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run

We're Not Very Worried About Edgewise Therapeutics' (NASDAQ:EWTX) Cash Burn Rate

Edgewise Therapeutics, Inc. Appoints Arlene Morris to Its Board of Directors

Edgewise Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Edgewise Therapeutics, Inc., Annual General Meeting, Jun 07, 2024

Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)

Price target increased by 16% to US$30.50

Edgewise Therapeutics: Behind The Massive Rally

Edgewise Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)

General Counsel notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Edgewise Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $240.000002 million.

General Counsel notifies of intention to sell stock

Co-Founder recently sold US$1.6m worth of stock

Co-Founder notifies of intention to sell stock

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics, Inc. Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

New major risk - Revenue and earnings growth

Edgewise Therapeutics Announces Expansion of Their Edg-5506 Clinical Program in Duchenne Muscular Dystrophy (Duchenne)

Edgewise Therapeutics, Inc. Announces Initiation of GRAND CANYON, a Global Pivotal Study of EDG-5506 in Becker Muscular Dystrophy (Becker)

Edgewise Therapeutics, Inc. Begins Dosing First-In-Human Phase 1 Trial of EDG-7500

Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans

Price target increased by 17% to US$27.40

Edgewise Therapeutics, Inc. Announces Positive 12-Month Topline Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

New minor risk - Share price stability

Price target increased by 15% to US$27.40

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Price target increased by 19% to US$28.75

We Think Edgewise Therapeutics (NASDAQ:EWTX) Can Afford To Drive Business Growth

Edgewise Therapeutics, Inc. Appoints Marc Semigran as Chief Development Officer

Edgewise Therapeutics Announces Initiation of Lynx Phase 2 Clinical Trial of Edg-5506 for the Treatment of Duchenne Muscular Dystrophy

Edgewise Therapeutics, Inc. Announces Positive 6-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy

Edgewise Therapeutics proposes $100M stock offering plan

Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

General Counsel notifies of intention to sell stock

Edgewise Therapeutics, Inc. Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy

General Counsel exercised options and sold US$74k worth of stock

Price target increased to US$30.00

Edgewise Therapeutics GAAP EPS of -$0.32 beats by $0.02

Companies Like Edgewise Therapeutics (NASDAQ:EWTX) Are In A Position To Invest In Growth

Edgewise Therapeutics Now Enrolling Canyon Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)

General Counsel exercised options and sold US$65k worth of stock

Edgewise Therapeutics, Inc.(NasdaqGS:EWTX) dropped from Russell 2000 Growth Index

Edgewise Therapeutics Inc. Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular

General Counsel exercised options and sold US$226k worth of stock

Price target decreased to US$25.60

General Counsel notifies of intention to sell stock

Price target increased to US$31.00

Edgewise Therapeutics, Inc. Anticipates Initiation of Phase 2 Trials in Individuals with BMD (NCT05291091) in the Second Quarter of 2022 and BMD in the Second Half of 2022

High number of new directors

Edgewise Therapeutics, Inc. Announces the Initiation of an Edgewise-Funded Observational Trial in Individuals with BMD

We're Hopeful That Edgewise Therapeutics (NASDAQ:EWTX) Will Use Its Cash Wisely

Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD)

High number of new directors

Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) on January 5, 2022, and Initiates ARCH Follow-On Open Label BMD Study